Strategies for postmarketing surveillance of drugs for rare diseases

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 265-268

  Kesselheim, A S ^a   Gagne, J J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DATABASES, BIBLIOGRAPHIC; DATABASES, FACTUAL; HUMANS; NATURAL HISTORY; OBSERVATIONAL STUDY AS TOPIC; ORPHAN DRUG PRODUCTION; PRODUCT SURVEILLANCE, POSTMARKETING; RARE DISEASES; REGISTRIES; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84894505841     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.218     Document Type: Article

References (24)

1. Adequate and well-controlled studies. Title 21 Code of Federal Regulations, pt. 314, sec. 126 (2007).
2. Coté, T., Kelkar, A., Xu, K., Braun, M.M. & Phillips, M.I. Orphan products: an emerging trend in drug approvals. Nat. Rev. Drug Discov. 9, 84 (2010).
3. Butlen-Ducuing, F., Rivière, F., Aarum, S. & Llinares-Garcia, J. European Medicines Agency support mechanisms fostering orphan drug development. Drug News Perspect. 23, 71-81 (2010).
4. Joppi, R., Bertele', V. & Garattini, S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur. J. Clin. Pharmacol. 69, 1009-1024 (2013).
5. Sasinowski, F.J. Quantum of effectiveness evidence in FDA's approval of orphan drugs: cataloguing FDA's flexibility in regulating therapies for persons with rare disorders. National Organization for Rare Disorders. (2011).
6. Kesselheim, A.S., Myers, J.A. & Avorn, J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 305, 2320-2326 (2011).
7. Mitsumoto, J., Dorsey, E.R., Beck, C.A., Kieburtz, K. & Griggs, R.C. Pivotal studies of orphan drugs approved for neurological diseases. Ann. Neurol. 66, 184-190 (2009).
8. Goodman, J.L. FDA's efforts on rare and neglected diseases 23 June 2010. .
9. European Medicines Agency. Cystadane: scientific discussion. (2007).
10. Wedatilake, Y. et al. SURF1 deficiency: a multi-centre natural history study. Orphanet J. Rare Dis. 8, 96 (2013).
11. US Food and Drug Administration. Workshop on natural history studies of rare diseases 16-17 May 2012. .
12. Carey, J.C. The importance of case reports in advancing scientific knowledge of rare diseases. Adv. Exp. Med. Biol. 686, 77-86 (2010).
13. Chow, S.C. & Chang, M. Adaptive design methods in clinical trials -a review. Orphanet J. Rare Dis. 3, 11 (2008).
14. van der Lee, J.H., Wesseling, J., Tanck, M.W. & Offringa, M. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. J. Clin. Epidemiol. 61, 324-330 (2008).
15. Kantarjian, H. et al. Results of a randomized study of 3 schedules of lowdose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109, 52-57 (2007).
16. Statland, J.M. et al.; Consortium for Clinical Investigation of Neurologic Channelopathies. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 308, 1357-1365 (2012).
17. Gupta, S., Faughnan, M.E., Tomlinson, G.A. & Bayoumi, A.M. A framework for applying unfamiliar trial designs in studies of rare diseases. J. Clin. Epidemiol. 64, 1085-1094 (2011).
18. Hackett, A., Gillard, J. & Wilcken, B. n of 1 trial for an ornithine transcarbamylase deficiency carrier. Mol. Genet. Metab. 94, 157-161 (2008).
19. Velentgas, P. et al. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Pharmacoepidemiol. Drug Saf. 17, 1226-1234 (2008).
20. Maro, J.C. et al. Design of a national distributed health data network. Ann. Intern. Med. 151, 341-344 (2009).
21. Platt, R., Wilson, M., Chan, K.A., Benner, J.S., Marchibroda, J. & McClellan, M. The new Sentinel Network-improving the evidence of medical-product safety. N. Engl. J. Med. 361, 645-647 (2009).
22. European Platform for Patients' Organisations, Science and Industry. Workshop on patients' registries for rare disorders: need for data collection to increase knowledge on rare disorders and optimize disease management and care. (2009).
23. Eichler, H.G. et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426-437 (2012).
24. Woodcock, J. Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin. Pharmacol. Ther. 91, 378-380 (2012).